Immunostaining as a diagnostic aid in cytopathologic study of upper urinary tract urothelial carcinoma

Acta Cytologica

Volumn 53, Issue 6, 2009, Pages 611-618

  Mai, Kien T ^a,b   Teo, Iris ^a,b   Robertson, Susan J ^a,b   Marginean, E Celia ^a,b   Islam, Shahidul ^a,b   Yazdi, Hossein M ^c,d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d CBLPath Laboratory   (United States)

Author keywords

Cytology; Immunohistochemistry; Ureter; Urothelial carcinoma

Indexed keywords

CD20 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CELL ADHESION; CONTROLLED STUDY; CYTOPATHOLOGY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEPHROURETERECTOMY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; URETER; URINARY TRACT CARCINOMA; UROTHELIUM;

EID: 73949126462     PISSN: 00015547     EISSN: 19382650     Source Type: Journal    
DOI: 10.1159/000325400     Document Type: Article

References (33)

1. Kirkali Z, Tuzel E: Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol 2003;47:155-169
2. Shiraishi K, Eguchi S, Mohri J, Kamiryo Y: Role of ureteroscopic biopsy in the management of upper urinary tract malignancy. Int J Urol 2003;10:627-630
3. Guarnizo E, Pavlovich CP, Seiba M, Carlson DL, Vaughan ED, Sosa RE: Ureteroscopic biopsy of upper tract urothelial carcinoma: Improved diagnostic accuracy and histopathological considerations using a multi-biopsy approach. J Urol 2000;163:52-55
4. Abdel-Razzak OM, Ehya H, Cubler-Goodman A, Bagley DH: Ureteroscopic biopsy in the upper urinary tract. Urology 1994;44:451-457
5. Gögüs C, Baltaci S, Sahinli S, Türkölmez K, Bedük Y, GcTgüs O: Value of selective upper tract cytology for recognition of upper tract tumors after treatment of superficial bladder cancer. Int J Urol 2003;10:243-246
6. Chen GL, El-Gabry EA, Bagley DH: Surveillance of upper urinary tract transitional cell carcinoma: The role of ureteroscopy, retrograde pyelography, cytology and urinalysis. J Urol 2000;164:1901-1904
7. Sadek S, Soloway MS, Hook S, Civantos F: The value of upper tract cytology after transurethral resection of bladder tumor in patients with bladder transitional cell cancer. J Urol 1999;161: 77-79; discussion 79-80
8. Dodd LG, Johnston WW, Robertson CN, Layfield LJ: Endoscopic brush cytology of the upper urinary tract: Evaluation of its efficacy and potential limitations in diagnosis. Acta Cytol 1997;41:377-384
9. Raica M, Mederle O, loiart I: Upper urinary tract washing in the diagnosis of transitional cell carcinoma of the renal pelvis and calices: A comparison with voided urine. Rom J Morphol Embryol 1995;41:101-105
10. Bian Y, Ehya H, Bagley DH: Cytologic diagnosis of upper urinary tract neoplasms by ureteroscopic sampling. Acta Cytol 1995;39:733-740
11. Kannan V: Papillary transitional-cell carcinoma of the upper urinary tract: Acytological review. Diagn Cytopathol 1990;6:204-209
12. Guarnizo E, Pavlovich CP, Seiba M, Carlson DL, Vaughan ED Jr, Sosa RE: Ureteroscopic biopsy of upper tract urothelial carcinoma: Improved diagnostic accuracy and histopathological considerations using a multi-biopsy approach. J Urol 2000;163:52-55
13. Andersen JR, Kristensen JK: Ureteroscopic management of transitional cell tumors. Scand J Urol Nephrol 1994;28:153-157
14. Martínez-Piñeiro JA, García Matres MJ, Martínez-Piñeiro L: Endourological treatment of upper tract urothelial carcinomas: Analysis of a series of 59 tumors. J Urol 1996;156:377-385
15. Grasso M, Fraiman M, Levine M: Ureteropyeloscopic diagnosis and treatment of upper urinary tract urothelial malignancies. Urology 1999;54:240-246
16. Seifman BD, Montie JE, Wolf JS Jr: Prospective comparison between hand-assisted laparoscopic and open surgical nephroureterectomy for urothelial cell carcinoma. Urology 2001 ;57:133-137
17. Suh RS, Faerber GJ, Wolf JS Jr: Predictive factors for applicability and success with endoscopic treatment of upper tract urothelial carcinoma. J Urol 2003;170:2209-2216
18. Lam JS, Gupta M: Ureteroscopic management of upper tract transitional cell carcinoma. Urol Clin North Am Rev 2004;31:115-128
19. Palou J, Piovesan LF, Huguet J, Salvador J, Vicente J, Villavicencio H: Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: Recurrence and long-term followup. J Urol 2004;172:66-69
20. Johnson GB, Grasso M: Ureteroscopic management of upper urinary tract transitional cell carcinoma. Curr Opin Rev Urol 2005;15:89-93
21. Siracusano S, Niccolini B, Knez R, Tiberio A, Benedetti E, Bonin S, Ciciliato S, Pappagallo GL, Belgrano E, Stanta G: The simultaneous use of telomerase, cytokeratin 20 and CD4 for bladder cancer detection in urine. Eur Urol 2005;47:327-333
22. Lin S, Hirschowitz SL, Williams C, Shintako P, Said J, Rao JY: Cytokeratin 20 as an immunocytochemical marker for detection of urothelial carcinoma in atypical cytology: Preliminary retrospective study on archived urine slides. Cancer Detect Prev 2001 ;25:202-209
23. Bhatia A, Dey P, Kumar Y, Gautam U, Kakkar N, Srinivasan R, Nijhawan R: Expression of cytokeratin 20 in urine cytology smears: A potential marker for the detection of urothelial carcinoma. Cytopathology 2007;18:84-86
24. Alsheikh A, Mohamedali Z, Jones E, Masterson J, Gilks CB: Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors: World Health Organization/International Society of Urologie Pathology. Mod Pathol 2001;14:267-272
25. Ramos D, Navarro S, Villamón R, Gil-Salom M, Llombart-Bosch A: Cytokeratin expression patterns in low-grade papillary urothelial neoplasms of the urinary bladder. Cancer 2003;97:1876-1883
26. van Oers JM, Wild PJ, Burger M, Denzinger S, Stoehr R, Rosskopf E, Hofstaedter F, Steyerberg EW, Klinkhammer-Schalke M, Zwarthoff EC, van der Kwast TH, Hartmann A: FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol 2007;52:760-768
27. Melissourgos ND, Kastrinakis NG, Skolarikos A, Pappa M, Vassilakis G, Gorgoulis VG, SaIIa C: Cytokeratin-20 immunocytology in voided urine exhibits greater sensitivity and reliability than standard cytology in the diagnosis of transitional cell carcinoma of the bladder. Urology 2005;66:536-541
28. Pu XY, Wang ZP, Chen YR, Wang XH, Wu YL, Wang HP: The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine. J Cancer Res Clin Oncol 2008;134:659-665
29. Ribal MJ, Mengual L, Marin M, Algaba F, Ars E, Fernández PL, Oliva R, Villavicencio H, Alcaraz A: Molecular staging of bladder cancer with RT-PCR assay for CK20 in peripheral blood, bone marrow and lymph nodes: Comparison with standard histological staging. Anticancer Res 2006;26:411-419
30. Christoph F, Weikert S, Wolff I, Schostak M, Tabiti K, Müller M, Miller K, Schrader M: Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder. Cancer Lett 2007;245:121-126
31. Rotem D, Cassel A, Lindenfeld N, Mecz Y, Sova Y, Resnick M, Stein A: Urinary cytokeratin 20 as a marker for transitional cell carcinoma. Eur Urol 2000;37:601-604
32. Inoue T, Nakanishi H, lnada K, Hioki T, Tatematsu M, Sugimura Y: Real time reverse transcriptase polymerase chain reaction of urinary cytokeratin 20 detects transitional cell carcinoma cells. J Urol 2001;166:2134-2141
33. Holmäng S, Johansson SL: Urothelial carcinoma of the upper urinary tract: Comparison between the WHO/ISUP 1998 consensus classification and WHO 1999 classification system. Urology 2005;66:274-278